சுயஷ் பிரசாத் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுயஷ் பிரசாத். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுயஷ் பிரசாத் Today - Breaking & Trending Today

Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer

Published: May 13, 2021

Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry
Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin

DALLAS (BUSINESS WIRE) Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer. Ms. Newman will oversee program and portfolio management, as well as translational sciences, and will report to Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Taysha’s Chie ....

Suyash Prasad , Development Officer , Bayer Healthcare Pharmaceuticals Inc , Head Of Research , Shire Ltd , Regulatory Affairs , Berlex Inc , Regulatory Affairs At Biomarin Pharmaceutical Inc , Taysha Gene Therapies Inc , Regulatory Affairs At Astellas Gene Therapies , Sarcode Bioscience Inc , Sequus Pharmaceuticals Inc , Oregon State University , Ut Southwestern Gene Therapy Program , Gene Therapies , Omary Newman , Chief Development , Chief Medical Officer , Senior Vice President , Astellas Gene Therapies , Audentes Therapeutics , Quality Assurance , Bioscience Inc , Biomarin Pharmaceutical , Sequus Pharmaceuticals , Vedere Bio ,

Taysha Gene Therapies, Inc. (TSHA) Q1 2021 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) Q1 2021 Earnings Call Transcript
Motley Fool Transcribing
© The Motley Fool
Logo of jester cap with thought bubble.
Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Q1 2021 Earnings Call
Operator
Welcome to the Taysha Gene Therapies first-quarter 2021 financial results and corporate update conference call. [Operator instructions] As a reminder, this call is being recorded today, May 11, 2021. I will now turn the call over to Dr. Kimberly Lee, senior vice president of corporate communications and investor relations.
Please go ahead.
Senior Vice President of Corporate Communications and Investor Relations
Good morning and welcome to Taysha s first-quarter 2021 financial results and corporate update conference call. Joining me on today s call are RA Session II, Taysha s president, CEO, and founder; Dr. Suyash Prasad, chief medical officer and head of R&D and Kamran Alam, chief financial office ....

United States , North Carolina , Saudi Arabia , Kimberly Lee , Novartis Avexis , Rachel Bailey , Raju Prasad William Blair , Kamran Alam , Salveen Richter Goldman Sachs , Dennis Lal , Salveen Richter , Sarah Sinnett , Matthew Harrison , Suyash Prasad , Steven Gray , Fred Porter , Raju Prasad , William Blair , Yale University , Motley Fool Taysha Gene Therapies Inc , Morgan Stanley , Yong Hui Jiang At Yale University , Genomics Institute , Goldman Sachs , Exchange Commission , Taysha Gene Therapies Inc ,

Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Progra

Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Progra
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United States , Kimberly Lee , Suyash Prasad , Steven Gray , Head Of Research , Company Contact , Development Of Taysha , National Institutes Of Health , Drug Administration , Exchange Commission , Taysha Gene Therapies Inc , Corporate Communications , European Medicines Agency , Devices Agency , National Institute Of Neurological Disorders , Ut Southwestern Gene Therapy Program , Chief Scientific Advisor , Taysha Gene Therapies , National Institutes , Chief Executive Officer , National Institute , Neurological Disorders , Motor Function Measure , Chief Medical Officer , Medical Devices Agency , Gene Therapies ,

Young but ambitious Taysha lays out $76M for commercial gene therapy plant

RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies)
Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site.
Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and commercial gene therapy production. It’s also due to receive up to $9.4 million in state and local incentives for the project, Taysha said in a release. ....

North Carolina , United States , Suyash Prasad , Fred Porter , Queen University , University Of Texas Ut Southwestern Medical Center , Health Canada , Taysha Gene Therapies , Optimal Scale Up , Tech Transfer , Moral Small , Southwestern Medical Center , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , சுயஷ் பிரசாத் , ஃப்ரெட் போர்டர் , ராணி பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம் , ஆரோக்கியம் கனடா , தாய்ஷ்ா கீந் சிகிச்சைகள் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , தென்மேற்கு மருத்துவ மையம் ,

Taysha Gene Therapies Announces Queen's University's Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis | DNA RNA and Cells

Hits: 889
TSHA-101 to be first bicistronic vector evaluated in human clinical trials; TSHA-101 designed to deliver both HEXA and HEXB transgenes within a single AAV9 vector construct
TSHA-101 CTA is the second clinical trial clearance received, in addition to TSHA-118’s open investigational new drug application for CLN1
Interim data from Phase 1/2 trial anticipated in 2021
DALLAS, TX, USA I December 21, 2020 I Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that Queen’s University in Ontario, Canada, received Clinical Trial Application (CTA) approval from Health Canada for its investigator-sponsored Phase 1/2 trial exploring TSHA-101, Taysha’s investigational AAV9-based gene therapy, for the treatment of infantile GM2 gangliosi ....

United States , Suyash Prasad , Jagdeeps Walia , Head Of Research , I Taysha Gene Therapies Inc , Queen University , Development Of Taysha , Drug Administration , Kingston Health Sciences Centre , Queen University In Ontario , Health Canada , Research Department Of Pediatrics , Taysha Gene Therapies Announces Queen , Clinical Trial Application Approval , United Statesi December , Taysha Gene Therapies , Clinical Trial Application , Chief Medical Officer , Clinical Geneticist , Associate Professor Head , Medical Genetics , Kingston Health Sciences , Orphan Drug , Rare Pediatric Disease , ஒன்றுபட்டது மாநிலங்களில் , சுயஷ் பிரசாத் ,